相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Treatment of Cognitive Impairment in Schizophrenia: Potential Value of Phosphodiesterase Inhibitors in Prefrontal Dysfunction
Marlies Van Duinen et al.
CURRENT PHARMACEUTICAL DESIGN (2015)
Molecular dynamics-based discovery of novel phosphodiesterase-9A inhibitors with non-pyrazolopyrimidinone scaffolds
Zhe Li et al.
MOLECULAR BIOSYSTEMS (2015)
Thieno[2,3-d]pyrimidine based derivatives as kinase inhibitors and anticancer agents
Eman Z. Elrazaz et al.
FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
Clinical and Molecular Genetics of the Phosphodiesterases (PDEs)
Monalisa F. Azevedo et al.
ENDOCRINE REVIEWS (2014)
Discovery of 2-(Cyclopentylamino)thieno[3,2-d]pyrimidin-4(3H)-one Derivatives as a New Series of Potent Phosphodiesterase 7 Inhibitors
Kentaro Kawai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Advances in targeting cyclic nucleotide phosphodiesterases
Donald H. Maurice et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Phosphodiesterases as Therapeutic Targets for Alzheimer's Disease
Ana Garcia-Osta et al.
ACS CHEMICAL NEUROSCIENCE (2012)
PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter
Jun-Jiang Chen et al.
CANCER SCIENCE (2012)
Thieno[2,3-d]pyrimidinedione derivatives as antibacterial agents
Mahender B. Dewal et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2012)
An unheard benefit of Cialis
Wanda Layman et al.
NATURE MEDICINE (2012)
The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents
P. H. Hutson et al.
NEUROPHARMACOLOGY (2011)
Mammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions
Sharron H. Francis et al.
PHYSIOLOGICAL REVIEWS (2011)
Synthesis and screening of some novel fused thiophene and thienopyrimidine derivatives for anti-avian influenza virus (H5N1) activity
Aymn E. Rashad et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2010)
Design and Synthesis of Tetrahydropyridothieno[2,3-d]pyrimidine Scaffold Based Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors: The Role of Side Chain Chirality and Michael Acceptor Group for Maximal Potency
Chia-Hsien Wu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Phosphodiesterase inhibitors and the eye
Nathan M. Kerr et al.
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2009)
Oral Phosphodiesterase Type 5 Inhibitors: Nonerectogenic Beneficial Uses
Taymour Mostafa
JOURNAL OF SEXUAL MEDICINE (2008)
Multiple conformations of phosphodiesterase-5 - Implications for enzyme function and drug development
Huanchen Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Synthesis of some thienopyrimidine derivatives
Fatma E. M. El-Baih et al.
MOLECULES (2006)
Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents
C Lugnier
PHARMACOLOGY & THERAPEUTICS (2006)
Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development
YH Jeon et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2005)
Structural basis for the activity of drugs that inhibit phosphodiesterases
GL Card et al.
STRUCTURE (2004)
Identification and characterization of a new human type 9 eGMP-specific phosphodiesterase splice variant (PDE9A5) - Differential tissue distribution and subcellular localization of PDE9A variants
P Wang et al.
GENE (2003)
Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules
BJ Sung et al.
NATURE (2003)
分享论文
